Anticardiolipin antibodies are immune proteins that mistakenly target cardiolipin, a fat molecule found in cell membranes throughout your body. Their presence signals that your immune system may be attacking the lining of your blood vessels and the surface of your platelets, raising the risk of abnormal blood clots. These antibodies are one of the key markers used to diagnose antiphospholipid syndrome (APS), a condition affecting roughly 50% of people with lupus and a smaller number of people with no other autoimmune disease.
How These Antibodies Cause Problems
Cardiolipin is a type of phospholipid, a building block of cell membranes. In healthy people, the immune system ignores it. When anticardiolipin antibodies form, they bind to negatively charged phospholipids on the surface of platelets and the cells lining blood vessels. To latch on, the antibodies typically need a helper protein called beta-2 glycoprotein I, which acts as a bridge between the antibody and the cell surface.
Once attached, these antibodies set off a chain of events that promotes clotting. They damage the lining of blood vessels, which triggers platelets to stick together and activate clotting factors. They also suppress production of prostacyclin, a natural substance that normally keeps blood flowing smoothly by preventing clots. The combined effect is a blood vessel environment that strongly favors clot formation, in both arteries and veins.
When anticardiolipin antibodies work alongside another type of antiphospholipid antibody called lupus anticoagulant, the effect on platelet activation is significantly amplified. Neither antibody alone enhances clotting as powerfully as the two together, which is why doctors often test for both.
Conditions Linked to Anticardiolipin Antibodies
The most important condition associated with these antibodies is antiphospholipid syndrome. APS can occur on its own (called primary APS) or alongside another autoimmune disease like lupus (called secondary APS). About 8% of people diagnosed with primary APS eventually develop lupus, suggesting the two conditions share underlying biology.
The complications tied to these antibodies are driven almost entirely by abnormal clotting. They include deep vein thrombosis (blood clots in the legs or arms), pulmonary embolism (clots that travel to the lungs), stroke, transient ischemic attacks, low platelet counts, and formation of clots on heart valves. High levels of the IgM type of anticardiolipin antibody are also associated with autoimmune hemolytic anemia, where the immune system destroys red blood cells. Many people with these antibodies develop livedo reticularis, a purple or reddish lacy pattern visible just under the skin.
There is also a historical connection to syphilis testing. In the 1940s, doctors discovered that some women with lupus tested positive for syphilis despite never having the infection. The substance both tests reacted to turned out to be cardiolipin. About 1 in 5 people with lupus had this false-positive syphilis result, which was actually the first recognized test for antiphospholipid antibodies.
What a Positive Test Means
Anticardiolipin antibodies come in three types: IgG, IgM, and IgA. Standard reference ranges classify results as follows:
- Normal: IgG below 15 GPL units/mL, IgM below 12.5 MPL units/mL
- Indeterminate: IgG between 15 and 20, IgM between 12.5 and 20
- Positive: IgG above 20, IgM above 20
Not all types carry equal weight. IgG anticardiolipin is the strongest independent risk factor for blood clots. In one study of lupus patients, those with persistently elevated IgG levels had an 80% higher rate of clotting events. IgM levels, by contrast, did not show a statistically significant link to clot risk. IgA is rarer as an isolated finding and is not currently included in the formal classification criteria for APS, though emerging evidence suggests it may also independently raise clotting risk.
A single positive test does not mean you have APS. Diagnosing antiphospholipid syndrome requires at least two positive tests spaced at least 12 weeks apart, combined with a clinical event such as a blood clot or pregnancy complication. This 12-week gap is critical because many positive results are temporary.
Why a Positive Result Can Be Temporary
Viral infections are a well-known trigger for transient anticardiolipin antibodies. Cytomegalovirus, hepatitis C, HIV, and other infections can all prompt the immune system to produce these antibodies briefly. The key difference is that infection-related anticardiolipin antibodies generally do not require beta-2 glycoprotein I as a cofactor, which is why they typically do not cause clotting. Once the infection clears, the antibodies usually disappear.
In rare cases, infection-triggered antibodies can cause clotting events. There are documented cases of people developing deep vein thrombosis and pulmonary embolism during a primary cytomegalovirus infection, with the antibodies vanishing completely after recovery. This is why repeat testing at 12 weeks is essential before drawing conclusions about long-term risk.
Pregnancy Risks
Anticardiolipin antibodies pose a serious threat during pregnancy. The two greatest risk factors for pregnancy loss are high levels of IgG anticardiolipin and a history of previous miscarriage. Women with both of these factors face up to an 80% risk of losing a current pregnancy without treatment. The antibodies can also contribute to preeclampsia, eclampsia, and restricted fetal growth, though the evidence for these associations is less consistent.
With treatment, outcomes improve substantially. For women experiencing recurrent miscarriages (three or more), the standard approach combines low-dose aspirin with a blood-thinning injection during pregnancy. Women who have had previous clotting events typically need a stronger blood thinner throughout pregnancy, switching from their usual oral medication to an injectable form, ideally before the sixth week of pregnancy.
How Anticardiolipin Antibodies Are Managed
Management depends entirely on whether you have had a clotting event or pregnancy complication, or whether the antibodies were found incidentally on a blood test.
If you have never had a clot, current guidelines recommend low-dose aspirin (75 to 100 mg daily) as a preventive measure, particularly if you have a high-risk antibody profile. This is especially relevant during situations that independently raise clotting risk, such as surgery, prolonged immobility, or hormonal contraceptive use.
If you have already experienced a blood clot, the picture changes significantly. Long-term anticoagulation with a blood thinner (typically warfarin) is the standard treatment, with regular blood monitoring to keep clotting time in a target range. For most patients with venous or arterial clots, this means lifelong treatment because the risk of recurrence remains high as long as the antibodies persist. Patients who have had a stroke may be managed differently depending on their age and antibody levels. Some may do well with aspirin alone, while others need full anticoagulation.
The commitment to lifelong blood thinners is one of the more difficult realities of this diagnosis. Stopping anticoagulation carries a meaningful risk of another clot, so the decision to continue treatment is revisited periodically based on whether the antibodies remain detectable on repeat testing.